Anti-CREBBP antibody (ab2832)
Key features and details
- Rabbit polyclonal to CREBBP
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-CREBBP antibody
See all CREBBP primary antibodies -
Description
Rabbit polyclonal to CREBBP -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Non human primates
-
Immunogen
Synthetic peptide corresponding to Human CREBBP aa 162-176.
Sequence:ATSSPATSQTGPGIC
(Peptide available asab4916) -
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 99% PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Primary antibody notes
Cyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators that have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB (cyclic AMP-responsive enhancer binding protein), c-Fos, c-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD.Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes.As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.Single point mutations in CBP have been proposed as causative factors in the developmental abnormalities of Rubinstein-Taybi syndrome (RTS).Although both CBP and p300 appear to function similarly, the inability of p300 to rescue CBP malfunction iRTS suggests intrinsic functional differences between CBP and p300. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
ChIP Related Products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab2832 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (3) |
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 265 kDa (predicted molecular weight: 265 kDa).
|
| IHC-P | (1) |
1/1000 - 1/5000.
|
| ICC/IF |
1/100.
|
| Notes |
|---|
|
WB
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 265 kDa (predicted molecular weight: 265 kDa). |
|
IHC-P
1/1000 - 1/5000. |
|
ICC/IF
1/100. |
Target
-
Function
Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300. -
Involvement in disease
Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies. -
Sequence similarities
Contains 1 bromo domain.
Contains 1 KIX domain.
Contains 2 TAZ-type zinc fingers.
Contains 1 ZZ-type zinc finger. -
Domain
The KIX domain mediates binding to HIV-1 Tat. -
Post-translational
modificationsMethylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX. -
Cellular localization
Cytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 1387 Human
- Entrez Gene: 12914 Mouse
- Omim: 600140 Human
- SwissProt: Q92793 Human
- SwissProt: P45481 Mouse
- Unigene: 459759 Human
- Unigene: 132238 Mouse
- Unigene: 392384 Mouse
-
Alternative names
- CBP antibody
- CBP_HUMAN antibody
- CREB binding protein antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)
Immunofluorescent analysis of MCF-7 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CREBBP antibody (ab2832)IHC image of CREBBP staining in human pancreas formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab2832, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)Immunofluorescent analysis of HeLa cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CREBBP antibody (ab2832)Immunohistochemical analysis of FFPE mouse colon tissue, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Heat antigen retrieval performed with 10mM Sodium Citrate (pH 6) for 8-15 minutes. Tissue blocked with 3% H2O2-methanol for 15 minutes at room temperature. Incubation with ab2832 diluted 1/2000 in 3% BSA-PBS overnight at 4°C. Counterstaining with hematoxylin.
-
Immunocytochemistry/ Immunofluorescence - Anti-CREBBP antibody (ab2832)Immunofluorescent analysis of NIH-3T3 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Nuclei were stained with DAPI (blue).
-
Western blot - Anti-CREBBP antibody (ab2832)ab2832 using HeLa cell lysate. ab2832 using HeLa cell lysate.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (57)
ab2832 has been referenced in 57 publications.
- Doi T et al. Involvement of activator protein-1 family members in β-catenin and p300 association on the genome of PANC-1 cells. Heliyon 8:e08890 (2022). PubMed: 35198763
- Feng D et al. BMSC-EV-derived lncRNA NORAD Facilitates Migration, Invasion, and Angiogenesis in Osteosarcoma Cells by Regulating CREBBP via Delivery of miR-877-3p. Oxid Med Cell Longev 2022:8825784 (2022). PubMed: 35281474
- Cao Y et al. ZFP36 protects lungs from intestinal I/R-induced injury and fibrosis through the CREBBP/p53/p21/Bax pathway. Cell Death Dis 12:685 (2021). PubMed: 34238924
- Diesch J et al. Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. Nat Commun 12:6060 (2021). PubMed: 34663789
- Huang YH et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther 6:10 (2021). PubMed: 33431788